Watson Mick
Genome Biol. 2014 Feb 25;15(2):108. doi: 10.1186/gb4165.
Human (clinical) genome sequencing is the biggest potential market in DNA sequencing, and it is this market that all of the sequencing companies are striving to capture. In another article in this issue of Genome Biology, Neil Hall expresses some concern over the limitation of Illumina's newly announced Hiseq X Ten platform to human indeed, at face value this does appear strange. The fact that Illumina have presented PhiX data from the X Ten confirms that there is no limitation inherent to the technology. The limitation is one of licensing. However, those involved in human genome sequencing will not be surprised by the move.
人类(临床)基因组测序是DNA测序领域最大的潜在市场,所有测序公司都在努力抢占这个市场。在本期《基因组生物学》的另一篇文章中,尼尔·霍尔对Illumina新推出的Hiseq X Ten平台仅限于人类测序表示了一些担忧——确实,从表面上看这似乎很奇怪。Illumina展示了来自X Ten平台的PhiX数据,这一事实证实了该技术本身并无限制。限制在于许可方面。然而,从事人类基因组测序的人对这一举动不会感到惊讶。